IL152625A0 - SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES HOMOLOGOUS TO AMYLOID beta FOR INDUCTION OF AN IMMUNE RESPONSE TO AMYLOID beta AND AMYLOID DEPOSITS - Google Patents

SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES HOMOLOGOUS TO AMYLOID beta FOR INDUCTION OF AN IMMUNE RESPONSE TO AMYLOID beta AND AMYLOID DEPOSITS

Info

Publication number
IL152625A0
IL152625A0 IL15262501A IL15262501A IL152625A0 IL 152625 A0 IL152625 A0 IL 152625A0 IL 15262501 A IL15262501 A IL 15262501A IL 15262501 A IL15262501 A IL 15262501A IL 152625 A0 IL152625 A0 IL 152625A0
Authority
IL
Israel
Prior art keywords
amyloid
amyloid beta
immune response
induction
deposits
Prior art date
Application number
IL15262501A
Other languages
English (en)
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Publication of IL152625A0 publication Critical patent/IL152625A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL15262501A 2000-05-22 2001-05-22 SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES HOMOLOGOUS TO AMYLOID beta FOR INDUCTION OF AN IMMUNE RESPONSE TO AMYLOID beta AND AMYLOID DEPOSITS IL152625A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20557800P 2000-05-22 2000-05-22
PCT/US2001/016322 WO2001090182A2 (en) 2000-05-22 2001-05-22 Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits

Publications (1)

Publication Number Publication Date
IL152625A0 true IL152625A0 (en) 2003-06-24

Family

ID=22762767

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15262501A IL152625A0 (en) 2000-05-22 2001-05-22 SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES HOMOLOGOUS TO AMYLOID beta FOR INDUCTION OF AN IMMUNE RESPONSE TO AMYLOID beta AND AMYLOID DEPOSITS
IL152625A IL152625A (en) 2000-05-22 2002-11-03 Synthetic but not amyloidogenic immunogenic peptides equivalent to amyloid b to elicit an immune response to amyloid b and amyloid deposits

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL152625A IL152625A (en) 2000-05-22 2002-11-03 Synthetic but not amyloidogenic immunogenic peptides equivalent to amyloid b to elicit an immune response to amyloid b and amyloid deposits

Country Status (14)

Country Link
US (3) US6713450B2 (es)
EP (1) EP1284998B1 (es)
JP (1) JP2003534351A (es)
CN (1) CN1249085C (es)
AT (1) ATE286072T1 (es)
AU (2) AU2001274873B2 (es)
CA (1) CA2408925A1 (es)
DE (1) DE60108111T2 (es)
ES (1) ES2238049T3 (es)
IL (2) IL152625A0 (es)
NZ (1) NZ521939A (es)
PT (1) PT1284998E (es)
WO (1) WO2001090182A2 (es)
ZA (1) ZA200207992B (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7148324B1 (en) * 1998-12-14 2006-12-12 Dendreon Corporation Compositions and methods for enhancement of major histocompatibility complex class I restricted antigen presentation
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
JP5025871B2 (ja) * 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
CA2400838C (en) * 2000-02-21 2013-04-23 Pharmexa A/S Novel method for down-regulation of amyloid
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US20040191264A1 (en) * 2001-02-19 2004-09-30 Nielsen Klaus Gregorius Synthetic vaccine agents
US7097837B2 (en) * 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US20030130484A1 (en) * 2001-03-20 2003-07-10 Gordon David J. Inhibitors and disassemblers of fibrillogenesis
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
CA2466841A1 (en) * 2001-11-21 2003-06-05 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1575529A4 (en) * 2002-07-17 2007-08-08 Intellect Neurosciences Inc PEPTIDES AND METHOD FOR THE INVESTIGATION OF IMMUNOGENOUS PEPTIDE VACCINES AGAINST ALZHEIMER DISEASE
EP1560850A2 (en) * 2002-11-14 2005-08-10 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
US20070010435A1 (en) 2002-12-19 2007-01-11 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
GB0310270D0 (en) * 2003-05-03 2003-06-11 Univ Edinburgh Biomolecular devices
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
EA009559B1 (ru) 2003-12-17 2008-02-28 Элан Фармасьютикелз, Инк. КОНЪЮГАТЫ Aβ ИММУНОГЕННЫХ ПЕПТИДНЫХ НОСИТЕЛЕЙ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
KR20070100234A (ko) * 2004-10-06 2007-10-10 히로시 모리 변이형 아밀로이드 단백질
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
EP1838349A1 (en) * 2004-12-15 2007-10-03 Neuralab, Ltd. Amyloid beta antibodies for use in improving cognition
WO2006066049A2 (en) * 2004-12-15 2006-06-22 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
CA2912012C (en) 2005-05-05 2018-05-29 Sensient Flavors Inc. Production of beta-glucans and mannans
KR20080090408A (ko) * 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
KR101439828B1 (ko) * 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
JP5033868B2 (ja) 2006-03-23 2012-09-26 バイオアークティック ニューロサイエンス アーベー 改良型プロトフィブリル選択的抗体及びその使用
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20090123488A1 (en) * 2006-08-14 2009-05-14 Thymon, Llc Compositions and methods for the treatment and prophylaxis of Alzheimer's disease
CA2660830A1 (en) * 2006-08-14 2008-02-21 Gideon Goldstein Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of hiv-1
WO2008070284A2 (en) 2006-10-16 2008-06-12 Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute Amyloid beta peptides and methods of uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008099917A1 (ja) * 2007-02-15 2008-08-21 Fukuoka University 抗hmgb-1抗体を含む臓器移植拒絶抑制剤
EP2123299A4 (en) * 2007-02-15 2011-10-05 Univ Kyushu Nat Univ Corp THERAPEUTIC AGENT FOR INTERSTITIAL PULMONARY DISEASE COMPRISING ANTI-HMGB-1 ANTIBODY
EP2123297A4 (en) 2007-02-15 2011-10-12 Univ Kumamoto THERAPEUTIC AGENT COMPRISING AN ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO HMGB-1 AS ACTIVE INGREDIENT
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US7618944B2 (en) * 2007-03-01 2009-11-17 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
MX2009011127A (es) * 2007-04-18 2010-03-10 Janssen Alzheimer Immunotherap Metodo de prevencion y tratamiento de angiopatia amiloide cerebral.
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
KR101478995B1 (ko) 2007-11-16 2015-01-12 더 락커펠러 유니버시티 원섬유 형태의 베타­아밀로이드 단백질에 대해 특이적인 항체
NZ590324A (en) * 2008-07-01 2012-08-31 Nederlanden Staat Vaccine against amyloid folding intermediate
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
TWI508976B (zh) * 2009-04-21 2015-11-21 Univ Rockefeller 對β－類澱粉蛋白之基原纖維形式具專一性之抗體
US8409584B2 (en) 2009-05-05 2013-04-02 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
EP2440234A4 (en) * 2009-06-10 2013-11-06 Univ New York IMMUNOLOGICAL TARGETING OF PATHOLOGICAL TAU PROTEINS
CN101920008B (zh) * 2009-06-15 2013-07-31 浙江仙琚制药股份有限公司 包含Aβ40多肽和铝佐剂的制剂以及纯化Aβ40多肽的方法
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
US9926353B2 (en) 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
US8906382B2 (en) 2011-07-19 2014-12-09 New York University Method for treating amyloid disease
KR102564384B1 (ko) 2014-07-10 2023-08-07 바이오악틱 에이비 개선된 Aβ 프로토피브릴 결합 항체
US11970521B2 (en) * 2016-08-20 2024-04-30 Arizona Board Of Regents On Behalf Of The University Of Arizona Neuroprotective beta amyloid core peptides and peptidomimetic derivatives
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
WO2023161527A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE202940T1 (de) 1994-05-25 2001-07-15 John Mcmichael Mittel und methoden zur behandlung von plaque- krankheiten
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
EP1033998B1 (en) 1997-12-03 2005-10-19 Neuralab, Ltd. Suppressing beta-amyloid-related changes in alzheimer's disease

Also Published As

Publication number Publication date
PT1284998E (pt) 2005-06-30
ES2238049T3 (es) 2005-08-16
CN1444598A (zh) 2003-09-24
WO2001090182A3 (en) 2002-05-23
IL152625A (en) 2009-12-24
US20020077288A1 (en) 2002-06-20
CN1249085C (zh) 2006-04-05
WO2001090182A2 (en) 2001-11-29
ZA200207992B (en) 2003-07-02
US6713450B2 (en) 2004-03-30
DE60108111T2 (de) 2005-12-08
US20040043935A1 (en) 2004-03-04
EP1284998A2 (en) 2003-02-26
US7427655B2 (en) 2008-09-23
NZ521939A (en) 2004-04-30
US7700107B2 (en) 2010-04-20
AU7487301A (en) 2001-12-03
US20090081204A1 (en) 2009-03-26
ATE286072T1 (de) 2005-01-15
JP2003534351A (ja) 2003-11-18
AU2001274873B2 (en) 2006-10-05
DE60108111D1 (de) 2005-02-03
CA2408925A1 (en) 2001-11-29
EP1284998B1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
IL152625A0 (en) SYNTHETIC IMMUNOGENIC BUT NON-AMYLOIDOGENIC PEPTIDES HOMOLOGOUS TO AMYLOID beta FOR INDUCTION OF AN IMMUNE RESPONSE TO AMYLOID beta AND AMYLOID DEPOSITS
WO2003045128A3 (en) SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID β, PRION PROTEIN, AMYLIN, α-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
MY125202A (en) Vaccine
DE3852761T3 (de) Saponin-hilfsmittel.
WO2004032829A3 (en) Immunostimulatory compositions and methods of stimulating an immune response
DK1326634T3 (da) Vaccinepræparat der omfatter et antigen og et peptid med adjuvansegenskaber
WO2007067681A3 (en) Immunostimulatory compositions and methods
MX343744B (es) Antigenos de neisseria meningitidis y composiciones que los contienen.
EP1090039A4 (en) PEPTIC COMPOSITION AS AN IMMUNOGEN FOR TREATING ALLERGY
TW200730189A (en) Novel composition
PL344593A1 (en) Attenuated mutants of salmonella
BR0012424A (pt) Peptìdeos meningocócicos antigênicos
WO2004112825A3 (en) Combinations of tumor-associated antigens for the treatment of various types of cancers
MY125000A (en) Novel compositions
IL153680A0 (en) Aplidine derivatives and methods for the preparation thereof
DK0876398T3 (da) Induktion af immunrespons med ønskede determinanter
ATE364395T1 (de) Konjugat-impfstoffe zur vorbeugung der zahnkaries
HK1048819A1 (en) Glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
WO2004078099A3 (en) Compositions and methods for the generation of protective immune response against malaria
WO2002047613A3 (en) Immunogenic cancer peptides and uses thereof
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
NZ514027A (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
DK1161250T3 (da) Immunstimulerende bakteriemembranfraktioner i cancerbehandling
IL150977A (en) Use of protein source for preparation of a nutitional composition for maintaining or improving the synthesis of mucins
AU2001267613A1 (en) Adjuvant composition comprising FHA protein or fragment of FHA protein in free form